Baker McKenzie advises Bristol Myers Squibb on its investment in GlycoEra AG

Baker McKenzie advised Bristol-Myers Squibb Company ("BMS") on its investment into GlycoEra AG ("GlycoEra") in its extended series A financing round. In its series A financing round, GlycoEra raised funds to further advance its preclinical programs. BMS joins existing investors which include 5AM Ventures, Roche Venture Fund and Sofinnova Partners. 

The proceeds will be used to support the development of GlycoEra and its platform technology. GlycoEra’s innovative platform enables high-throughput design and production of candidates for fast and deep degradation of pathogenic proteins.

Baker McKenzie advised BMS on all legal aspects of the financing.

Matthias Trautmann (partner M&A, Zurich) led the Baker McKenzie team, which consisted of Raphael Schneuwly (associate M&A, Zurich), Maxim Tsotsorin (senior associate M&A, Palo Alto) and James Tenrai (associate M&A, Palo Alto).